Program
afimetoran
Also written as “BMS-986256” and “Afimetoran”.
Its studies are mostly in Lupus Erythematosus, Cutaneous · Lupus Erythematosus, Systemic, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 100 open or running | phase 1since Aug 15, 2018 | Aug 15, 2018 | none ahead |
| Beeline Medicines | 22 open or running | phase 3since Oct 5, 2026 | May 19, 2021 | Apr 2030phase 3 · NCT07881120 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2018First study: phase 1 study in Healthy ParticipantsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03634995 · 118 enrolled · United States
- May 14, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT03950960 · 15 enrolled · United States
- Jun 26, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04016753 · 32 enrolled · United States
- Jul 22, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04039373 · 15 enrolled · United States
- Feb 12, 2020Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04269356 · 8 enrolled · United States
- Jul 13, 20202 phase 1 studiesBristol-Myers Squibb · NCT04470778, NCT04493541
- May 19, 2021Beeline Medicines's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Beeline MedicinesBeeline Medicines · NCT04895696 · 248 enrolled · United States, Argentina, Australia and more
- Jun 24, 2021Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04941755 · 22 enrolled · United States
- May 10, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05866627 · 32 enrolled · United Kingdom
- Jun 5, 2023Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05901714 · 65 enrolled · United States
- Oct 5, 2026Phase 3 study in Lupus Erythematosus, CutaneousPhase 3 reachedBeeline Medicines · NCT07881120 · 390 planned · United States
Ahead
- Apr 2030Primary completion: phase 3 study in Lupus Erythematosus, CutaneousBeeline Medicines · NCT07881120
TargetBeta
“Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 14 |
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 12 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07881120Lupus Erythematosus, Cutaneous · United States | 3 | Recruiting | Beeline Medicines | Apr 2030 | 390 |
| NCT05901714Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Apr 11, 2024 | 65 |
| NCT05866627Healthy Volunteers · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Sep 29, 2023 | 32 |
| NCT04941755Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 24, 2021 | 22 |
| NCT04895696Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Beeline Medicines | Jun 12, 2026 | 248 |
| NCT04493541Lupus Erythematosus, Cutaneous · Germany | 1 | Completed | Bristol-Myers Squibb | Apr 21, 2023 | 13 |
| NCT04470778Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 21, 2021 | 35 |
| NCT04269356Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Mar 30, 2021 | 8 |
| NCT04039373Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Sep 18, 2019 | 15 |
| NCT04016753Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Feb 21, 2020 | 32 |
| NCT03950960Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Jul 31, 2019 | 15 |
| NCT03634995Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Oct 9, 2019 | 118 |
How it is read
Names in the registry
- “BMS-986256”, 8 entries
- “Afimetoran”, 4 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Cutaneous, 2 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.